Systemic Lupus Erythematosus Clinical Trials

44 studies are recruiting for systemic lupus erythematosus in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

   The purpose of this study is to evaluate the ability of dapirolizumab pegol (DZP) as an add-on treatment to standard of care (SOC) medication to achieve clinically relevant long term improvement of moderate to severe disease activity.

   Stage

   Phase 3

   Ages

   16 and older

   Site

   Sl0044 50058, Avondale, Arizona

   Locations

   245 in total

   Run by

   UCB Biopharma SRL

   See if you can join NCT06617325 on ClinicalTrials.gov

2. Study of Systemic Lupus Erythematosus

   This protocol will evaluate patients with systemic lupus erythematosus (SLE) and their relatives to learn more about how the disease develops and changes over time. It will also study genetic factors that make a person susceptible to SLE. Patients 3 years of age and older with known or suspected SL…

   Stage

   Not phased

   Ages

   3 to 120

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

   See if you can join NCT00001372 on ClinicalTrials.gov

3. Safety of the Herpes Zoster Subunit Vaccine in Lupus

   This randomized, double-blind, placebo-controlled, non-inferiority crossover study will evaluate the Herpes Zoster Sunbit (HZ/su) vaccine in SLE patients in order to evaluate safety and immunogenicity in patients with variable baseline clinical activities, ages and immunosuppressant exposures. The …

   Stage

   Phase 4

   Ages

   18 to 90

   Site

   NYU Langone Health, New York, New York

   Locations

   2 in total

   Run by

   NYU Langone Health

   See if you can join NCT05559671 on ClinicalTrials.gov

4. Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants

   This open-label, Phase I study will assess the safety and tolerability of surovatamig and characterise its PK and PD following subcutaneous administration to participants with RA or SLE.

   Stage

   Phase 1

   Ages

   18 to 65

   Site

   Research Site, Fullerton, California

   Locations

   35 in total

   Run by

   AstraZeneca

   See if you can join NCT07201558 on ClinicalTrials.gov

5. A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)

   This study is open to adults with systemic lupus erythematosus (SLE). The purpose of this study is to find out whether a medicine called BI 3000202 helps people with SLE. The study tests different doses of BI 3000202 and aims to find the best dose for people with this condition. Participants are pu…

   Stage

   Phase 2

   Ages

   18 to 74

   Site

   Arthritis & Osteoporosis Medical Center, Inc - La Palma, La Palma, California

   Locations

   139 in total

   Run by

   Boehringer Ingelheim

   See if you can join NCT07409181 on ClinicalTrials.gov

6. A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 in Adult Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)

   Systemic lupus erythematosus (SLE) is a chronic, systemic autoimmune disease characterized by B cell hyperactivity. Rheumatoid Arthritis (RA) is a chronic inflammatory disease causing pain, stiffness, swelling and loss of joint function. The purpose of this study is to assess the pharmacokinetics, …

   Stage

   Phase 1

   Ages

   18 to 75

   Site

   Pinnacle Research Group /ID# 278677, Anniston, Alabama

   Locations

   15 in total

   Run by

   AbbVie

   See if you can join NCT07607964 on ClinicalTrials.gov

7. A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.

   The purpose of this study is to measure the safety, tolerability, PK, and PD of AZD5492 administered subcutaneously in adult participants with SLE or IIM or RA Study details include: • The study duration will be a minimum of 180 days in addition to the screening period. Additional follow-up visits …

   Stage

   Phase 1

   Ages

   18 to 70

   Site

   Research Site, Anniston, Alabama

   Locations

   38 in total

   Run by

   AstraZeneca

   See if you can join NCT06916806 on ClinicalTrials.gov

8. Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).

   The purpose of this study is to evaluate long-term safety and tolerability of ianalumab in participants with systemic lupus erythematosus who have previously completed the treatment period in one of the two SIRIUS-SLE core studies (CVAY736F12301 or CVAY736F12302).

   Stage

   Phase 3

   Ages

   12 to 100

   Site

   Pinnacle Research Group Llc, Anniston, Alabama

   Locations

   164 in total

   Run by

   Novartis Pharmaceuticals

   See if you can join NCT06133972 on ClinicalTrials.gov

9. RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus

   RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus

   Stage

   Phase 1

   Ages

   12 to 65

   Site

   University of California Irvine, Orange, California

   Locations

   23 in total

   Run by

   Cabaletta Bio

   See if you can join NCT06121297 on ClinicalTrials.gov

10. Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders

    The goal of Safety Lead-In is to confirm the safety of tafasitamab when given to patients with SSc, SLE, and LN. The goal of Phase 1 is to find the recommended dose of AD-PluReceptor-NK cells in combination with tafasitamab and lymphodepleting chemotherapy that can be given to patients with the dis…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    MD Anderson Cancer Center, Houston, Texas

    Locations

    2 in total

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT06434363 on ClinicalTrials.gov

11. Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

    This phase Ib trial studies the side effects of nivolumab and to see how well it works alone and in combination with other treatments, such as ipilimumab, cabozantinib, platinum containing therapy, and fluoropyrimidine, in treating patients with autoimmune disorders and cancer that has spread from …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of California Davis Comprehensive Cancer Center, Sacramento, California

    Locations

    52 in total

    Run by

    National Cancer Institute (NCI)

    See if you can join NCT03816345 on ClinicalTrials.gov

12. A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases

    The main objective is to assess the safety and tolerability of inebilizumab in adult participants with active and refractory systemic lupus erythematosus (SLE) with nephritis (Subprotocol A) and to assess the safety and tolerability of subcutaneous (SC) blinatumomab in adult participants with activ…

    Stage

    Phase 2

    Ages

    18 to 75

    Site

    HonorHealth Research and Innovation Institute, Scottsdale, Arizona

    Locations

    58 in total

    Run by

    Amgen

    See if you can join NCT06570798 on ClinicalTrials.gov

13. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus

    The goal of this clinical trial is to learn if VENT-03 works to treat patients with cutaneous lupus erythematosus (CLE) who may or may not have systemic lupus erythematosus (SLE). Another goal is to learn about the safety of VENT-03 and how it is processed by the body. The main questions it aims to…

    Stage

    Phase 2

    Ages

    18 to 80

    Site

    Investigative Site, Beverly Hills, California

    Locations

    34 in total

    Run by

    Ventus Therapeutics U.S., Inc.

    See if you can join NCT07260877 on ClinicalTrials.gov

14. An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants

    A Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), Efficacy, and Safety of Anifrolumab in Children with Moderate to Severe Active Systemic Lupus Erythematosus (SLE)

    Stage

    Phase 3

    Ages

    5 to 17

    Site

    Research Site, Phoenix, Arizona

    Locations

    103 in total

    Run by

    AstraZeneca

    See if you can join NCT05835310 on ClinicalTrials.gov

15. A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus

    The purpose of the SUNFLOWER study is to describe clinical outcomes, including DORIS remission, achieved following the initiation of anifrolumab 120 mg SC once weekly (QW) as add-on therapy to an anti-malarial, with or without GC; in patients not in LLDAS at enrolment. Patients will be naïve to any…

    Stage

    Phase 3

    Ages

    18 to 70

    Site

    Research Site, La Palma, California

    Locations

    107 in total

    Run by

    AstraZeneca

    See if you can join NCT07430306 on ClinicalTrials.gov

16. The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD

    Background: People with systemic lupus erythematosus (SLE) are at risk of developing complications in their blood vessels. This can increase the risk of heart attacks or stroke. No medications have been effective at reducing this risk in people with lupus. Objective: To test whether a drug (anifrol…

    Stage

    Phase 2

    Ages

    18 to 80

    Site

    National Institutes of Health Clinical Center, Bethesda, Maryland

    Run by

    National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

    See if you can join NCT05440422 on ClinicalTrials.gov

17. Anifrolumab Pregnancy Study

    This is a non-interventional multi-database post-authorisation study to assess pregnancy-related safety data from women with SLE exposed to Anifrolumab.

    Stage

    Not phased

    Ages

    18 to 130

    Site

    Research Site, Cary, North Carolina

    Run by

    AstraZeneca

    See if you can join NCT07049653 on ClinicalTrials.gov

18. Transcutaneous Vagus Nerve Stimulation in SLE

    Systemic lupus erythematosus (SLE) is a chronic autoimmune inflammatory disease. Joint and muscle pain and fatigue are extremely common among patients and contribute to a reduced quality of life. Available therapies may be associated with significant side effects and many patients do not achieve an…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Feinstein Institutes for Medical Research, Manhasset, New York

    Run by

    Northwell Health

    See if you can join NCT06987565 on ClinicalTrials.gov

19. Prospective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users

    Prospective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users (PRIMULA Lac) is a Post Marketing Requirements (PMR) study designed to fulfill the FDA post-marketing requirements. The study will collect data about the presence of anifrolumab in human breast milk and…

    Stage

    Phase 4

    Ages

    18 to 130

    Site

    Research Site, Las Vegas, Nevada

    Run by

    AstraZeneca

    See if you can join NCT06594068 on ClinicalTrials.gov

20. HEALTH Home Urinalysis Testing

    Study participants enrolled in the SAMPLE Biorepository (s14-00487) who have provided permission to be contacted for future research will be enrolled and randomized (1:1) two-arm controlled) to either 1) perform weekly home-based proteinuria testing in addition to standard of care or 2) standard of…

    Stage

    Not phased

    Ages

    18 and older

    Site

    NYU Langone Health, New York, New York

    Run by

    NYU Langone Health

    See if you can join NCT07823478 on ClinicalTrials.gov

21. A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis

    The primary objective of this trial is to evaluate the efficacy and safety of FT819, comprised of allogeneic T cells that express a CD19-targeted CAR, following bendamustine administration in participants with refractory moderate-to-severe lupus nephritis, as assessed by the proportion of participa…

    Stage

    Phase 2

    Ages

    12 to 70

    Site

    Wallace Rheumatic Studies Center, Beverly Hills, California

    Locations

    12 in total

    Run by

    Fate Therapeutics

    See if you can join NCT07570862 on ClinicalTrials.gov

22. Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users

    PRIMULA Preg (Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users) is a prospective, observational cohort study designed to evaluate the association between anifrolumab exposure during pregnancy and subsequent adverse maternal, fetal, and infant outcomes. This study…

    Stage

    Not phased

    Ages

    Any age

    Site

    Research Site, Wilmington, North Carolina

    Run by

    AstraZeneca

    See if you can join NCT06659029 on ClinicalTrials.gov

23. Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease

    Hydroxychloroquine (HCQ) is a systemic lupus erythematosus (SLE) medication that has been very effective in reducing lupus disease activity and keeping patients stable with reduced symptoms. Despite a track record of safety with regard to infection compared to traditional immunosuppressive agents, …

    Stage

    Phase 3

    Ages

    55 and older

    Site

    University of California, Los Angeles, Los Angeles, California

    Locations

    12 in total

    Run by

    NYU Langone Health

    See if you can join NCT05799378 on ClinicalTrials.gov

24. Intervention to Improve Communication and Medication Adherence in Lupus

    CO-LEAD is an intervention to improve patient-provider communication and medication adherence among patients with systemic lupus erythematosus (SLE). The purpose of this study is to optimize the culturally appropriate delivery and test the effect of the CO-LEAD intervention, which includes the foll…

    Stage

    Not phased

    Ages

    18 to 90

    Site

    Duke University, Durham, North Carolina

    Run by

    Duke University

    See if you can join NCT06458075 on ClinicalTrials.gov

25. A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE), Sjogren's Disease (SjD) and Rheumatoid Arthritis (RA)

    Systemic lupus erythematosus (SLE) is a chronic, systemic autoimmune disease characterized by B cell hyperactivity. Sjorgren's disease (SjD) is a chronic, multisystem autoimmune disease characterized by lacrimal and salivary gland inflammation, with resultant dryness of the eyes and mouth and occas…

    Stage

    Phase 1

    Ages

    18 to 75

    Site

    Life Clinical Trials - Colonial Drive - Margate /ID# 276050, Margate, Florida

    Locations

    11 in total

    Run by

    AbbVie

    See if you can join NCT06977724 on ClinicalTrials.gov